1. Report Introduction

2. Hyperkalemia Market Overview at a Glance
2.1. Market Share Distribution of Hyperkalemia in 2017
2.2. Market Share Distribution of Hyperkalemia in 2027

3. Disease Background and Overview: Hyperkalemia
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Hyperkalemia in 7MM
4.3. Total Prevalent Patient Population of Hyperkalemia in 7MM – By Countries

5. Epidemiology of Hyperkalemia by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Hyperkalemia
5.1.3. Sub-Type Specific cases of the Hyperkalemia *
5.1.4. Sex- Specific Cases of the Hyperkalemia *
5.1.5. Diagnosed Cases of the Hyperkalemia
5.1.6. Treatable Cases of the Hyperkalemia
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Hyperkalemia
5.4.3. Sub-Type Specific cases of the Hyperkalemia *
5.4.4. Sex- Specific Cases of the Hyperkalemia *
5.4.5. Diagnosed Cases of the Hyperkalemia
5.4.6. Treatable Cases of the Hyperkalemia
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Hyperkalemia
5.5.3. Sub-Type Specific cases of the Hyperkalemia *
5.5.4. Sex- Specific Cases of the Hyperkalemia *
5.5.5. Diagnosed Cases of the Hyperkalemia
5.5.6. Treatable Cases of the Hyperkalemia
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Hyperkalemia
5.6.3. Sub-Type Specific cases of the Hyperkalemia *
5.6.4. Sex- Specific Cases of the Hyperkalemia *
5.6.5. Diagnosed Cases of the Hyperkalemia
5.6.6. Treatable Cases of the Hyperkalemia
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Hyperkalemia
5.7.3. Sub-Type Specific cases of the Hyperkalemia *
5.7.4. Sex- Specific Cases of the Hyperkalemia *
5.7.5. Diagnosed Cases of the Hyperkalemia
5.7.6. Treatable Cases of the Hyperkalemia
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Hyperkalemia
5.8.3. Sub-Type Specific cases of the Hyperkalemia *
5.8.4. Sex- Specific Cases of the Hyperkalemia *
5.8.5. Diagnosed Cases of the Hyperkalemia
5.8.6. Treatable Cases of the Hyperkalemia
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Hyperkalemia
5.9.3. Sub-Type Specific cases of the Hyperkalemia *
5.9.4. Sex- Specific Cases of the Hyperkalemia *
5.9.5. Diagnosed Cases of the Hyperkalemia
5.9.6. Treatable Cases of the Hyperkalemia

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Hyperkalemia

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Hyperkalemia
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Hyperkalemia : 7MM Market Analysis
12.1. 7MM Market Size of Hyperkalemia
12.2. 7MM Percentage Share of drugs marketed for Hyperkalemia
12.3. 7MM Market Sales of Hyperkalemia by Products

13. Hyperkalemia : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Hyperkalemia in United States
13.1.2. Percentage Share of drugs marketed for Hyperkalemia in United States
13.1.3. Market Sales of Hyperkalemia by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Hyperkalemia in Germany
13.2.1.2. Percentage Share of drugs marketed for Hyperkalemia in Germany
13.2.1.3. Market Sales of Hyperkalemia by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Hyperkalemia in France
13.2.2.2. Percentage Share of drugs marketed for Hyperkalemia in France
13.2.2.3. Market Sales of Hyperkalemia by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Hyperkalemia in Italy
13.2.3.2. Percentage Share of drugs marketed for Hyperkalemia in Italy
13.2.3.3. Market Sales of Hyperkalemia by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Hyperkalemia in Spain
13.2.4.2. Percentage Share of drugs marketed for Hyperkalemia in Spain
13.2.4.3. Market Sales of Hyperkalemia by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Hyperkalemia in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Hyperkalemia in United Kingdom
13.2.5.3. Market Sales of Hyperkalemia by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Hyperkalemia in Japan
13.3.2. Percentage Share of drugs marketed for Hyperkalemia in Japan
13.3.3. Market Sales of Hyperkalemia by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology
17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

*Indication Specific